fluorocholine and Breast-Neoplasms

fluorocholine has been researched along with Breast-Neoplasms* in 3 studies

Other Studies

3 other study(ies) available for fluorocholine and Breast-Neoplasms

ArticleYear
Incidental detection of breast cancer by 18F-fluorocholine PET/CT performed for primary hyperparathyroidism.
    Nuclear medicine review. Central & Eastern Europe, 2022, Volume: 25, Issue:1

    We present a case report of incidental detection of breast cancer in a female patient referred for 18F-fluorocholine (FCH) positron emission tomography/computed tomography (PET/CT) due to primary hyperparathyroidism. This imaging method was recently shown as more sensitive for the detection of metabolically hyperactive parathyroid glands than neck ultrasound and (2-metoksyizobutyloizonitryl labeled with technetium-99m) [99mTc]MIBI. Increased accumulation of FCH was found in the hyperactive parathyroid gland and unexpectedly in the right breast lesion. The surgery confirmed parathyroid adenoma. One month later right upper medial quadrantectomy confirmed breast carcinoma - a combination of invasive ductal carcinoma and intracystic papillary breast carcinoma. To the best of our knowledge, this is the first reporting of simultaneous detection of parathyroid adenoma and breast cancer by using 18F-fluorocholine PET/CT.

    Topics: Breast Neoplasms; Choline; Female; Humans; Hyperparathyroidism, Primary; Parathyroid Glands; Positron Emission Tomography Computed Tomography; Technetium Tc 99m Sestamibi

2022
Diagnostic Performance of Proton Magnetic Resonance Spectroscopy and 18F-Fluorocholine PET to Differentiate Benign From Malignant Breast Lesions.
    Clinical nuclear medicine, 2021, Nov-01, Volume: 46, Issue:11

    The aim of this study was to evaluate the diagnostic performance of the proton magnetic resonance spectroscopy (MRS) and 18F-fluorocholine (FCH) PET for suspicious breast findings on conventional imaging (mammography and breast ultrasound).. From September 2012 to December 2015, 37 women with 39 breast lesions on conventional imaging were enrolled and underwent proton MRS and FCH PET. The MRS parameters of choline signal-to-noise ratio (SNR), choline integral (I(cho)), and the PET parameters including SUVmax in the prone (SUV1) and supine (SUV2) positions were analyzed. Receiver operating characteristic curves with the area under the curve, sensitivity, and specificity under the optimal cutoff points for the different parameters were determined.. Twenty-three lesions (59%) were malignant, and 16 (41.0%) were benign. The malignant lesions tended to show significantly higher MRS and PET parameters than benign lesions (choline SNR, P = 0.007; I(cho), P = 0.003; SUV1 and SUV2, P < 0.0001). Fair to moderate correlations were noted between the choline SNR and PET parameters (SUV1, Spearman rank correlation coefficient, ρ = 0.477; SUV2, ρ = 0.483), as well as I(cho) and PET parameters (SUV1, ρ = 0.493; SUV2, ρ = 0.549). The SUV2 showed the highest diagnostic performance (area under the curve, 0.918). Using 2.5 as the optimal cutoff point, the SUV2 yields 89.5% sensitivity and 87.5% specificity for differentiating malignant from benign lesions.. The MRS parameters were fairly to moderately correlated with FCH PET parameters, and both could differentiate malignant from benign breast lesions with SUV2 showing best diagnostic performance.

    Topics: Breast Neoplasms; Choline; Female; Humans; Positron-Emission Tomography; Proton Magnetic Resonance Spectroscopy; Sensitivity and Specificity

2021
Detection of synchronous primary breast and prostate cancer by F-18 fluorocholine PET/CT.
    Clinical nuclear medicine, 2010, Volume: 35, Issue:2

    Topics: Aged; Breast Neoplasms; Choline; Humans; Male; Neoplasms, Multiple Primary; Positron-Emission Tomography; Prostatic Neoplasms; Tomography, X-Ray Computed

2010